Durvalumab treatment in combination with Chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer patients

Trial Identifier: D081RC00001
Sponsor: AstraZeneca
Collaborator:
European Network of Gynaecological Oncology Trial Groups (ENGOT)
GOG Foundation, Inc. (GOG Foundation)
Myriad Genetic Laboratories, Inc.
NCTID:: NCT03737643
Start Date: January 2019
Primary Completion Date: September 2023
Study Completion Date: May 2028
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations